Results 21 to 30 of about 183,390 (190)
Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study [PDF]
, 2014 Background: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. Methods: Women from a national observational study, exposed in pregnancy to either atazanavir or
. . . ]. +17 more
core +1 more source
Universitas Scientiarum, 2019 The HIV-1 protease plays an essential role in the replication cycle of HIV-1; therefore there is a direct need to develop novel inhibitors of the HIV-1 protease, which can cease the viral replication.
Ammara Akhtar, Waqar Hussain, Nouman Rasool3
doaj +1 more source
Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014 [PDF]
, 2016 Resistance to antiretroviral agents is a significant concern in the clinical management of HIV-infected individuals, particularly in areas of the world where treatment options are limited.
Aghasadeghi, M.R. +6 more
core +1 more source
HIV-2 Protease resistance defined in yeast cells
Retrovirology, 2006 Background Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue.
Raoult Didier +3 more
doaj +1 more source
Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance
, 2020 The HIV-1 protease is a major target of inhibitor drugs in AIDS therapies. The therapies are impaired by mutations of the HIV-1 protease that can lead to resistance to protease inhibitors.
Hemmateenejad, B., Weikl, T.
core +1 more source
In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1. [PDF]
, 2010 Although antiretroviral drug resistance is common in treated HIV infected individuals, it is not a consistent indicator of HIV morbidity and mortality.
Kitchen, Christina MR +2 more
core +2 more sources
HIV-1 Protease Inhibitors [PDF]
Clinical Infectious Diseases, 2000 Treatment of human immunodeficiency virus type 1 (HIV-1) infection with regimens that include protease inhibitors (PIs) has contributed to marked improvements in HIV-related disease progression and mortality. Five PIs are approved by the US Food and Drug Administration and have potent activity in vitro.
openaire +2 more sources
Investigation of Structural Dynamics of Enzymes and Protonation States of Substrates Using Computational Tools. [PDF]
, 2016 This review discusses the use of molecular modeling tools, together with existing experimental findings, to provide a complete atomic-level description of enzyme dynamics and function.
Chang, Chia-En A +3 more
core +2 more sources
Mangiferin, an Anti-HIV-1 Agent Targeting Protease and Effective against Resistant Strains
Molecules, 2011 The anti-HIV-1 activity of mangiferin was evaluated. Mangiferin can inhibit HIV-1ⅢB induced syncytium formation at non-cytotoxic concentrations, with a 50% effective concentration (EC50) at 16.90 μM and a therapeutic index (TI) above 140. Mangiferin also
Rui-Rui Wang +6 more
doaj +1 more source
Viruses, 2022 Drug-resistance-associated mutation in essential proteins of the viral life cycle is a major concern in anti-retroviral therapy. M46I, a non-active site mutation in HIV-1 protease has been clinically associated with saquinavir resistance in HIV patients.
Nilottam Rana +8 more
doaj +1 more source